Cysteine protease inhibitors as potential antiparasitic agents

Bibliography

• BARRETT AJ: Classification of peptidases. Methods EnzymoL (1994) 244:1–15.
   PubMedGoogle Scholar
• SAJID M, MCKERROW JH: Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. (2002) 120:1–21.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of the involvementof cysteine proteases in the life cycle of parasitic organisms.
   Google Scholar
• CHUNG YB, KONG Y, YANG HJ, KANG SY, CHO SY: Cysteine protease activities during maturation stages of Paragonimus westermani. J. Parasitol. (1997) 83:902–907.
   PubMedGoogle Scholar
• MCKERROW JH: Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action. Int. J. Parasitol. (1999) 29:833–837.
   PubMed Web of Science ®Google Scholar
• •In-depth review of the use of cysteine protease inhibitors for the treatment of parasitic diseases.
   Google Scholar
• TURK B, TURK D, SALVESEN GS: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. (2002) 8:1623–1637.
   PubMed Web of Science ®Google Scholar
• BROCKLEHURT K: A sound basis for pH-dependent kinetic studies on enzymes. Protein Eng. (1994) 7:291–299.
   PubMedGoogle Scholar
• TURK D, GUNCAR G, PODOBNIK M et al.: Revised definition of substrate binding sites of papain-like cysteine proteases. Biol. Chem. (1998) 379:137–147.
   PubMed Web of Science ®Google Scholar
• GILLMOR SA, CRAIK CS, FLETTERICK RJ: Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. (1997) 6:1603–1611.
   PubMed Web of Science ®Google Scholar
• WARD W, ALVARADO L, RAWLINGS ND, ENGEL JC, FRANKLIN C, McKERROW JH: A primitive enzyme for a primitive cell: the protease required for excystation of Giardia. Cell (1997) 89:437–444.
   PubMed Web of Science ®Google Scholar
• KONG Y, CHUNG YB, CHO SY, KANG SY: Cleavage of immunoglobulin G by excretory-secretory cathepsin S-like protease of Spirometra mansoni plerocercoid. Parasitology (1994) 109:611–621.
   PubMedGoogle Scholar
• CHUNG YB, KONG Y, J00 IJ, CHO SY, KANG SY: Excystment of Paragonimus westermani metacercariae by endogenous cysteine protease. J. Parasitol. (1995) 81:137–142.
   PubMedGoogle Scholar
• LECAILLE F, KALETA J, BROMME D: Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. (2002) 102:4459–4488.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of human and parasitic papain-like cysteine proteases.
   Google Scholar
• KARRER KM, PEIFFER SL, DITOMAS ME: Two distinct gene subfamilies within the family of cysteine protease genes. Proc. NatL Acad. Sci. USA (1993) 90:3063–3067.
   PubMed Web of Science ®Google Scholar
• LEROY V, THURAIRATNAM S: Cathepsin S inhibitors. Expert Opin. Ther. Patents (2004) 14:301–311.
   Web of Science ®Google Scholar
• CAI J, JAMIESON C, MOIR J et aL: Cathepsin K inhibitors, 2000-2004. Expert Opin. Ther. Patents (2004) 15:33–48.
   Google Scholar
• NAGLER DK, SULEA T, MENARD R: Full-length cDNA of human cathepsin F predicts the presence of a cystatin domain at the N-terminus of the cysteine protease zymogen. Biochem. Biophys. Res. Commun. (1999) 257:313–318
   PubMedGoogle Scholar
• WEX T, WEX H, BROEMME D: The human cathepsin F gene-a fusion product between an ancestral cathepsin and cystatin gene. Biol. Chem. (1999) 380:1439–1342.
   PubMed Web of Science ®Google Scholar
• KANG TH, YUN DH, LEE EH et aL: A cathepsin F of adult Clonorchis sinensis and its phylogenetic conservation in nematodes. Parasitology (2004) 128:195–207.
   PubMedGoogle Scholar
• TURK D, PODOBNIK M, KUHELJ R et al.: Crystal structures of human procathepsin B at 3.2 and 3.3 A resolution reveal an interaction motif between a papain-like cysteine protease and its peptide. FEBS Lett. (1996) 384:211–214.
   Google Scholar
• MUSIL D, ZUCIC D, TURK D et aL: The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. (1991) 10:2321–2330.
   Google Scholar
• QURAISHI 0, NAGLER DK, FOX T et al.: The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry (1999) 38:5017–5023.
   Google Scholar
• LIU LX, WELLER PF: Antiparasitic drugs. N EngL J. Med. (1996) 334:1178–1184.
   PubMed Web of Science ®Google Scholar
• URBINA JA: Chemotherapy of Chagas' disease. Curr. Pharm. Des. (2002) 8:287–295.
   PubMed Web of Science ®Google Scholar
• CAFFREY CR, SCORY S, STEVERDING D: Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr. Drug Targets. (2000) 1:155–62.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL PJ: Protease inhibitors. In: Antimalarial Chemotherapy: Mechanisms of Action, Resistance, and New Directions in Drug Discovery. Humana Press, NJ, USA (200 1) :325–344.
   Google Scholar
• ROSENTHAL PJ, LEE GK, SMITH RE: Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. (1993) 91:1052–1056.
   PubMed Web of Science ®Google Scholar
• ••Evidence supporting the use of cysteineprotease inhibitors in the treatment of murine malaria.
   Google Scholar
• SELZER PM, PINGEL S, HSIEH I et al.: Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc. Natl. Acad. Sci. USA. (1999) 96:11015–11022.
   PubMed Web of Science ®Google Scholar
• ENGEL JC, DOYLE PS, HSIEH I et al.: Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. (1998) 188:725–734.
   PubMed Web of Science ®Google Scholar
• ••Paper showing the use of cysteine proteaseinhibitors in the treatment of Chagas disease.
   Google Scholar
• ENGEL JC, DOYLE PS, PALMER J et aL:Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi. J. Cell Sci. (1998) 111:597–606.
   PubMed Web of Science ®Google Scholar
• •Paper demonstrating the action mechanism of cysteine protease inhibitors.
   Google Scholar
• SCORY S, CAFFREY CR, STIERHOF YD et al.: Trypanosoma brucei: killing of bloodstream forms in vitro and in vivo by the cysteine proteinase inhibitor Z-Phe-Ala-CHN2. Exp. ParasitoL (1999) 91:327–333.
   PubMed Web of Science ®Google Scholar
• •Effects of cysteine protease inhibitors for killing parasites.
   Google Scholar
• SEMENOV A, OLSON JE, ROSENTHAL PJ: Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob. Agents Chemother. (1998) 42:2254–2258.
   PubMed Web of Science ®Google Scholar
• POLTICELLI F, ZAINI G, BOLLI A et al.: Probing the cruzain S2 recognition subsite: a kinetic and binding energy calculation study. Biochemistry (2005) 44:2781–2789.
   PubMedGoogle Scholar
• SANDERSON PE: Small, noncovalent serine protease inhibitors. Med. Res. Rev. (1999) 19:179–197.
   PubMed Web of Science ®Google Scholar
• SHENAI BR, LEE BJ, ALVAREZ-HERNANDEZ A et al.: Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother. (2003) 47:154–160.
   PubMed Web of Science ®Google Scholar
• •Evaluation of cysteine protease inhibitors by SAR.
   Google Scholar
• MCKERROW JH, ENGEL JC, CAFFREY CR: Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg-. Med. Chem. (1999) 7:639–644.
   PubMed Web of Science ®Google Scholar
• •Review on the use of cysteine protease inhibitors in the treatment of parasitic infections.
   Google Scholar
• ROUSH WR, CHENG J, KNAPP-REED B et al.: Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cystein protease cruzain. Bioorg-. Med. Chem. Lett. (2001) 11:2759–2762.
   PubMedGoogle Scholar
• GOTZ MG, CAFFREY CR, HANSELL E et al.: Peptidyl allyl sulfones: a new class of inhibitors for clan CA cysteine proteases. Bioorg-. Med. Chem. (2004) 12:5203–5211.
   PubMedGoogle Scholar
• HUANG L, LEE A, ELLMAN JA: Identification of potent and selective mechanism-based inhibitors of the cysteine protease cruzain using solid-phase parallel synthesis. J. Med. Chem. (2002) 45:676–684.
   PubMed Web of Science ®Google Scholar
• LAKHDAR-GHAZAL F, BLONSKI C, WILLSON M, MICHELS P, PERIE J: Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Cuff. Top. Med. Chem. (2002) 2:439–456.
   PubMedGoogle Scholar
• DU X, GUO C, HANSELL E et al.: Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem. (2002) 45:2695–2707.
   PubMed Web of Science ®Google Scholar
• CHIBALE K, MUSONDA CC: The synthesis of parasitic cysteine protease and trypanothione reductase inhibitors. Curr. Med. Chem. (2003) 10:1863–1889.
   PubMedGoogle Scholar
• CHIYANZU I, HANSELL E, GUT Jet al.: Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg-. Med. Chem. Lett. (2003) 13:3527–3530.
   Google Scholar
• FUJII N, MALLARI JP, HANSELL EJ et al.: Discovery of potent thiosemicarbazone inhibitors of rhodesain and cruzain. Bioorg-. Med. Chem. Lett. (2005) 15:121–123.
   PubMed Web of Science ®Google Scholar
• GREENBAUM DC, MACKEY Z, HANSELL E et al.: Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. J. Med. Chem. (2004) 47:3212–3219.
   PubMed Web of Science ®Google Scholar
• DESAI PV, PATNY A, SABNIS Yet al.: Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. (2004) 47:6609–6615.
   Google Scholar
• •Identification of cysteine protease inhibitors as antiparasitic agents by virtual screening.
   Google Scholar
• FALGUEYRET JP, OBALLA RM, OKAMOTO 0 et al.: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem. (2001) 44:94–104.
   Google Scholar
• •Description of nonpeptidic reversible cysteine protease inhibitors of cathepsins K and L.
   Google Scholar
• ROBICHAUD J, BAYLY C, OBALLA R et al.: Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4291–4295.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Carbamate-based reversible inhibitors of cathepsin S and cathepsin K. Expert Opin. Ther. Patents (2003) 13:1077–1080.
   Web of Science ®Google Scholar
• HUANG L, ELLMAN JA: General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain. Bioorg-. Med. Chem. Lett. (2002) 12:2993–2996.
   PubMedGoogle Scholar
• LEUNG D, ABBENANTE G, FAIRLIE DP: Protease inhibitors: current status and future prospects. J. Med. Chem. (2000) 43:305–341.
   PubMed Web of Science ®Google Scholar
• FENWICK AE, GARNIER B, GRIBBLE AD et al.: Solid-phase synthesis of cyclic alkoxyketones, inhibitors of the cysteine protease cathepsin K. Bioorg-. Med. Chem. Lett. (2001) 11:195–198.
   PubMedGoogle Scholar
• BROEMME D, KALETA J: Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. (2002) 8:1639–1658.
   PubMedGoogle Scholar
• MARQUIS RW, RU Y, LOCASTRO SM et al.: Azepanone-based inhibitors of human and rat cathepsin K. J. Med. Chem. (2001) 44:1380–1395.
   PubMed Web of Science ®Google Scholar
• CROFT SL: The current status of antiparasite chemotherapy. Parasitology (1997) 114:S3–S15.
   Google Scholar
• •Review on the possibility of the use of cysteine protease inhibitors as antiparasitic agents.
   Google Scholar
• COOMBS GH, MOTTRAM JC: Parasite proteinase and amino acid metabolism: possibilities for chemotherapeutic exploitation. Parasitology (1997) 114:S61–S80.
   Google Scholar
• ABATH FG: Development of vaccines against human parasitic diseases: tools, current status and perspectives. Expert Opin. Investig. Drugs (2000) 9:301–310.
   PubMed Web of Science ®Google Scholar
• NA BK, KIM TS, ROSENTHAL PJ, LEE JK, KONG Y: Evaluation of cysteine proteases of Plasmodium vivax as antimalarial drug targets: sequence analysis and sensitivity to cysteine protease inhibitors. ParasitoL Res. (2004) 94:312–317.
   PubMedGoogle Scholar
• ROSENTHAL PJ: Cysteine proteases of malaria parasites. Int. J. ParasitoL (2004) 34:1489-1499. Patents
   Google Scholar